Contributor Page
Oblon, McClelland, Maier & Neustadt, L.L.P
 
Email  |  Website  |  Articles
Contact Details
Tel: +1 703 413 3000
Fax: +1 703 413 2220
1940 Duke Street
Alexandria
VA 22314
United States
By Oblon, McClelland, Maier & Neustadt, L.L.P
The USPTO issued a release stating:
By Frank J. West
During the past decade, domestic and international corporations have seen the value of their US patent rights steadily erode.
By Philippe Signore
In its new 101 Guidance, the USPTO explains that a claim reciting "a judicial exception is not ‘directed to' the judicial exception if the judicial exception is integrated into a practical application of the judicial exception."
By Oblon, McClelland, Maier & Neustadt, L.L.P
The USPTO is seeking public comment on all the issues addressed by the two guidance documents.
By Oblon, McClelland, Maier & Neustadt, L.L.P
The fee schedule provides information and fee rates for products and services provided by the USPTO.
By Yuki Onoe
The USPTO has recently announced extension of Patents 4 Patients, also called as the Cancer Immunotherapy Pilot Program, until June 30, 2020.
By Oblon, McClelland, Maier & Neustadt, L.L.P
All pilot parameters remain the same as first implemented on June 29, 2016.
By W. Todd Baker, Lisa M. Mandrusiak
Supreme Court Asked to Decide if AIA Creates Standing for Any Party to Appeal PTAB Decisions.
By Matthew E. Barnet
They are structurally identical to the ends of DNA strands found in nature." Id. at 10-11
By Oblon, McClelland, Maier & Neustadt, L.L.P
Further information regarding any adjustments to the USPTO's operating status will be posted on the USPTO website and delivered to the news media.
By Eric Schweibenz, Alexander B. Englehart
The Notice of Investigation further indicates that the Office of Unfair Import Investigations will participate as a party in the investigation.
By Eric Schweibenz, Alexander B. Englehart
On December 7, 2018, Extang Corp. and Laurmark Enterprises, Inc. d/b/a BAK Industries—both of Ann Arbor, Michigan—filed a complaint requesting that the ITC commence an investigation pursuant to Section 337.
By Marc K. Weinstein
The statutory language for IPRs and PGRs supports this conclusion.
By Brian Darville
Defendants then moved for an award of attorneys' fees of approximately $600,000.
By Richard Kelly
In Roche Diagnostics the Federal Circuit continued its failure to recognize that diagnostic claims were not patent ineligible because they used a natural law.